A single specific amino acid residue in peptide antigens is sufficient to activate memory CTL: potential role of cross-reactive peptides in memory T cell maintenance.
In the present study, we examined the structural requirements of peptide Ags for productive interactions with the TCR of CTL. For this purpose, we used as a model a previously identified immunodominant epitope that represents the target of EBV-specific HLA-A11-restricted CTL responses. By the use of peptides having minimal sequence homology with the wild-type epitope, we demonstrated that it is possible to selectively expand and reactivate memory CTL precursors without triggering the lytic mechanisms of wild-type specific effectors. In fact, stimulation of PBL from EBV-seropositive donors by polyalanine analogues, sharing only the putative TCR contact residue with the natural epitope, exclusively induced clonal expansion and reactivation of EBV-specific memory CTL precursors. Interestingly, these polyalanine peptides failed to trigger the cytotoxic function of CTLs specific for the wild-type viral epitope. This clearly indicates that reactivation of memory CTL precursors and triggering of the cytotoxic function have different requirements. The same phenomenon was observed using as stimulators naturally occurring peptides carrying the appropriate TCR contact residue. These data strongly suggest that cross-reactive peptides may play an important role in the expansion and reactivation of CTL clones from the memory T cell pool, and may be involved in long-term maintenance of T cell memory.
Reali
E
E
Department of Biochemistry and Molecular Biology, University of Ferrara, Italy. reali.eva@hsr.it
Guerrini
R
R
Marastoni
M
M
Tomatis
R
R
Masucci
M G
MG
Traniello
S
S
Gavioli
R
R
D019943:Amino Acid Substitution; D000596:Amino Acids / Q000276:immunology* / Q000302:isolation & purification; D002461:Cell Line, Transformed; D003429:Cross Reactions; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry; D019309:Epstein-Barr Virus Nuclear Antigens / Q000737:chemistry / Q000276:immunology*; D015684:Gene Products, pol / Q000737:chemistry; D006678:HIV / Q000276:immunology; D015234:HLA-A Antigens / Q000737:chemistry; D059870:HLA-A11 Antigen; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D009842:Oligopeptides / Q000138:chemical synthesis / Q000276:immunology* / Q000494:pharmacology; D010455:Peptides / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology; D011948:Receptors, Antigen, T-Cell / Q000037:antagonists & inhibitors; D017386:Sequence Homology, Amino Acid; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000737:chemistry
D000596:Amino Acids; D018984:Epitopes, T-Lymphocyte; D019309:Epstein-Barr Virus Nuclear Antigens; D015684:Gene Products, pol; D015234:HLA-A Antigens; D059870:HLA-A11 Antigen; D009842:Oligopeptides; D010455:Peptides; D011948:Receptors, Antigen, T-Cell; D016159:Tumor Suppressor Protein p53; C019529:polyalanine